论文期刊

取消

高级检索

检索历史清除

首页> Cardiovascular toxicology> Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway.

Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway.

导出 LinkOut

翻译打印收藏纠错

作者： Gang,Zhou ^[1] ; Hui,Wu ^[2] ; Jian,Yang ^[3] ; Ming,Ye ^[4] ; Di,Liu ^[5] ; Yunzhao,Li ^[6] ; Dong,Zhang ^[1] ; Jing,Zhang ^[7] ; Qingzhuo,Yang ^[2] ; Yanfang,Liu ^[1]

作者单位： Institute of Cardiovascular Disease, China Three Gorges University, Yichang, 443003, China. ^[1] HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, 443003, China. ^[2] Department of Central Experimental Laboratory, Yichang Central People's Hospital, Yichang, 443003, China. ^[3] Institute of Cardiovascular Disease, China Three Gorges University, Yichang, 443003, China. wuhui@ctgu.edu.cn. ^[4] Department of Cardiology, Yichang Central People's Hospital, Yichang, 443003, China. wuhui@ctgu.edu.cn. ^[5] HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, 443003, China. wuhui@ctgu.edu.cn. ^[6] Department of Cardiology, Yichang Central People's Hospital, Yichang, 443003, China. ^[7]

关键词 Glucagon-like peptide-1 receptor (GLP-1R)Liraglutide Myocardial ischemia/reperfusion injury (MI/RI)Necroptosis PI3K/Akt pathway

主题词大鼠(Rats);动物(Animals);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);心肌再灌注损伤(Myocardial Reperfusion Injury);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);磷酸肌醇3-激酶(Phosphatidylinositol 3-Kinase);信号传导(Signal Transduction);糖尿病, 2型(Diabetes Mellitus, Type 2);细胞凋亡(Apoptosis);肌细胞, 心脏(Myocytes, Cardiac)

DOI 10.1007/s12012-023-09789-3

PMID 36934206

发布时间 2023-04-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Cardiovascular toxicology

Cardiovascular toxicology

2023年23卷3-4期

161-175页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷